Unless otherwise defined, the abbreviations and definitions used in the announcement dated 7 September 2020 shall apply herein.

The Board of Directors of HWGB (“Board”) is pleased to announce that following the submission of the Research Protocol, HWGB Biotech had today appointed Prima Nexus Sdn Bhd for the following services in conducting the research study titled “OPV As A Preventive Protection Against The SARS-Cov-2 Virus” (“Research Study”):

a)      Proposal design;

b)      Site and investigator identification;

c)      Study registration with the ethics committee and regulatory board;

d)      Study recruitment and study conduct;

e)      Measured outcome analysis;

f)       Report writing and statistical analysis; and

g)      Archiving of clinical data.

Apart from the above, the Board also wishes to announce that HWGB Biotech had today submitted a letter to MOH stating HWGB’s intention in seeking MOH’s support in expediting the approval for HWGB Biotech to carry out the Research Study and to explore potential collaboration with MOH in the Research Study. 

This is a positive step for HWGB Biotech in its efforts to expedite the entry of EBI’s Covid-19 vaccine for private sector use in Malaysia in the event EBI’s Covid-19 vaccine is proven effective for the preventive protection against Covid-19.

This announcement is dated 7 December 2020.